Nina Cosdon

Lodise breaks down significant findings from his 8 IDWeek 2022 posters.

Remdesivir was the first FDA-approved drug to fight COVID-19, but how has it held up against the latest variants?

It’s not enough to have accurate infectious disease diagnostics, they must be accessible to the patients most affected.

Encouraging ICU physicians to utilize rapid diagnostics, like the FilmArray Pneumonia Panel, may improve patient outcomes.

Sepsis diagnosis often takes days. Dr. Roy Davis and his team have developed a test that can diagnose sepsis in an hour.

A late-breaking IDWeek 2022 study found high seroprotection was achieved among people living with HIV after receiving 3 doses of a hepatitis B vaccine.

What makes Novavax’s COVID-19 booster different? The adjuvanted vaccine “has kept recognizing variants that arise,” says Novavax executive director Germán Áñez, MD.

Dr. Simon Portsmouth elaborates on the potential of Shionogi's cefiderocol, an up-and-coming agent in the fight against antimicrobial resistance.

At IDWeek 2022, Erica Stohs, MD, MPH, presented surprising findings about unnecessary antibiotics in a cohort coinfected with COVID-19 and pneumonia.

There is a significant need for C difficile treatments that don’t destroy the microbiome.

Despite no significant reduction in time to discharge or recovery, inhalable SNG001 may lessen common symptoms of “long COVID.”

Breakthrough COVID-19 infections were rare in fully vaccinated individuals, but the average breakthrough occurred just under 50 days after complete vaccination.

At IDWeek 2022, antimicrobial stewardship was front and center. However, not all tests are created equal.

Antimicrobial stewardship works, one IDWeek 2022 study found.

Shionogi shared positive clinical cure rates from their ongoing trial of Fetroja (cefiderocol) for difficult-to-treat Gram-negative infections.

Ahead of the IDWeek 2022 conference, GSK shared data from their phase 3 RSV vaccine trial.

Articles covering respiratory infections were our most-clicked this week.

Preliminary results from a phase 2/3 trial suggest Pfizer-BioNTech’s Omicron BA.4/BA.5 bivalent COVID-19 booster vaccine provides better protection for younger and older adults.

Pediatric populations are disproportionately affected by influenza. The first cell-based quadrivalent flu vaccine offers potential for greater vaccine effectiveness.

These were our most popular articles this week. Catch up with these trending infectious disease stories.

The FDA cleared zetomipzomib as an Investigational New Drug. A phase 2 clinical trial is the next step for this autoimmune hepatitis treatment.

The CDC is urging all eligible persons to receive a flu shot, but a new survey shows fewer adults are planning to get the vaccine this season.

Yasaswi Kislovskiy, MD, MSc, specialized in reproductive infectious disease to advocate for gender equity in health care.

Catch up on Contagion's top stories from the month of September.

C diff patients live in fear of a recurrence, says gastroenterologist Paul Feuerstadt, MD. RBX2660 has entered the FDA pipeline and looks to end this vicious cycle.

Uganda’s first Ebola outbreak in a decade raises concern due to its vaccine resistance.

The Vaccines and Related Biological Products Advisory Committee's (VRBPAC) positive vote follows the committee’s review of the data from the biologics license application (BLA) for RBX2660.

In 2020 alone, the COVID-19 pandemic may have caused an additional 10500 heart attacks, strokes, and other blood clot complications across England and Wales.

After positive top-line data from phase 3 trials for their meningococcal vaccine, MenABCWY, Pfizer intends to submit a Biologics License Application (BLA) to the FDA.

The AIDS Clinical Trials Group (ACTG) is launching a phase 3 trial to evaluate the safety and efficacy of tecovirimat to treat monkeypox in vulnerable populations.